Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study (ESDAC)

NCT02639585 Phase 4 UNKNOWN

We perform this study to identity efficacy and safety of Daclatasvir and Asunaprevir in real practice.

Details

Lead sponsor	Pusan National University Hospital
Phase	Phase 4
Status	UNKNOWN
Enrolment	32
Start date	2015-12
Completion	2017-06

Conditions

• Hepatitis C, Chronic

Interventions

• Daclinza and Sunvepra

Primary outcomes

• Sustained Virologic Responase — week 12 (after treatment)

Countries

South Korea